Home/Filings/4/0001654954-20-000310
4//SEC Filing

NIFFENEGGER KATHI 4

Accession 0001654954-20-000310

CIK 0001540159other

Filed

Jan 9, 7:00 PM ET

Accepted

Jan 10, 9:36 PM ET

Size

9.5 KB

Accession

0001654954-20-000310

Insider Transaction Report

Form 4
Period: 2020-01-08
NIFFENEGGER KATHI
Chief Financial Officer
Transactions
  • Award

    Common Shares

    2020-01-08$4.11/sh+1,218$5,0061,218 total(indirect: By Trust)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+914914 total(indirect: By Trust)
    Exercise: $4.80From: 2020-07-08Exp: 2023-07-08Common Shares (914 underlying)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+609609 total(indirect: By Trust)
    Exercise: $4.00From: 2020-07-08Exp: 2020-11-08Common Shares (609 underlying)
Footnotes (3)
  • [F1]The reported securities are included within 1,218 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share.
  • [F2]Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023.
  • [F3]Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020.

Issuer

Edesa Biotech, Inc.

CIK 0001540159

Entity typeother

Related Parties

1
  • filerCIK 0001620146

Filing Metadata

Form type
4
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 9:36 PM ET
Size
9.5 KB